-
1 Comment
Vaxil Bio Ltd is currently in a long term downtrend where the price is trading 44.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Vaxil Bio Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 51.2% to $-313K since the same quarter in the previous year.
Finally, its free cash flow fell by 148.6% to $-261K since the same quarter in the previous year.
Based on the above factors, Vaxil Bio Ltd gets an overall score of 1/5.
| ISIN | CA92243L1076 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | V |
| CurrencyCode | CAD |
| PE Ratio | None |
|---|---|
| Dividend Yield | None |
| Market Cap | 1M |
| Beta | -3.67 |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VXL.V using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
